Boston Scientific has agreed to acquire Bolt Medical, a California-based medical device company focused on developing new intravascular lithotripsy technologies. The news comes less than one year after Johnson & Johnson acquired IVL pioneers Shockwave Medical for $13 billion.

The new atrial shunt from Alleviant Medical was designed to treat heart failure without leaving a permanent implant behind. The FDA granted the technology its breakthrough device designation and approved additional research. 

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

Healthcare companies from all over the world are showing off their newest cardiovascular offerings at CES 2025 in Las Vegas.

Radial access is already the primary choice for many cardiologists performing PCI due to a lower risk of complications. The same appears to be true for secondary access during TAVR.

The FDA-approved Harmony TPVR system is now available to patients across the EU. Nina Goodheart, president of Medtronic’s structural heart and aortic business, described the news as a "significant milestone."

The popular GLP-1 receptor agonist appears to help limit adverse events and new-onset diabetes in patients with a history of CABG. Researchers shared the full study in the Journal of the American College of Cardiology.

Michael Reardon, MD, co-principal investigator of the ACURATE IDE trial, discussed updated data on what may have impacted that study's findings.

A care team in Illinois has performed the first heart procedure of its kind on a two-year-old patient diagnosed with Brugada syndrome. 

New research out of Denmark explored how undergoing TAVR may or may not influence the final year of a patient's life.